Login to Your Account



Clinic Roundup


Friday, October 25, 2013

• Cornerstone Pharmaceuticals Inc., of Cranbury, N.J., started a Phase II trial with CPI-613, its lead altered energy metabolism-directed drug candidate. The pilot study, sponsored by the Comprehensive Cancer Center of Wake Forest Baptist Medical Center, will evaluate the overall response rate for CPI-613 in patients with myelodysplastic syndrome who have been unresponsive to previous therapies. Secondary endpoints include overall survival, progression-free survival, safety and transfusion frequency.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription